Salesforce for biotech — the questions we actually get asked

IMPACT64.AI answers the questions senior biotech buyers ask most about Salesforce — platform choice versus Veeva, regulated fit under MHRA and FDA including CSV, Part 11 and GDPR, Agentforce safety, migration risk, realistic cost, and the operating model needed to sustain Salesforce from pre-commercial through commercial launch.

• Platform decision: Salesforce vs Veeva for biotech
• Regulated fit: GxP, MHRA, FDA, Part 11, GDPR
• Scaling Salesforce from pre-commercial to launch
• Agentforce, AI safety, EU AI Act readiness
• Migration, integration, Data Cloud, and operating model